Introduction
============

Kidney transplantation remains the best available treatment for end-stage kidney disease (ESKD). When successful, transplantation reduces mortality and improves the quality of life for most patients when compared with dialysis \[[@sfx117-B1]\]. However, the degree of pre-existing cardiovascular risk in kidney transplant recipients (KTR) is a major determinant of post-transplantation survival. Starting from Day 1, survival benefits are seen in patients with low and intermediate risk \[[@sfx117-B4]\]. Unfortunately, patients with high cardiovascular risk might not see a survival benefit for a period of up to 6--12 months after having a successful kidney transplant \[[@sfx117-B1], [@sfx117-B4]\]. It has been shown before that patients who are on the waiting list for transplantation have a better survival compared with non-listed dialysis patients \[[@sfx117-B1], [@sfx117-B4]\]. The most likely explanation for this observation is that the KTR group comprises patients who were carefully selected from the dialysis population, and they likely represent the healthiest individuals compared with those who were not listed for transplantation. In fact, it has been shown, in previous studies, that dialysis patients who were on the deceased-donor kidney transplantation waiting list were usually healthier and younger than non-listed dialysis patients \[[@sfx117-B5]\].

Waiting times for transplantation are on the rise and, subsequently, the burden of comorbid disease in patients awaiting transplantation is increasing. The main reason behind this is the shortage of heart-beating organs. The rate of growth of the chronic kidney disease/ESKD population has continued to increase while the transplant organs availability rate has not grown at the same pace. During the last decade, the number of adults waiting for a kidney transplant almost doubled in the USA \[[@sfx117-B8]\]. Every year, waiting times are getting longer. Around 10 000 patients, approximately, wait for at least 11 years to receive a kidney transplant \[[@sfx117-B8]\]. To keep up with the pace of the rapidly expanding pool of patients waiting for a kidney transplant, optimization of the use of available allografts is required. This increases pressure on many transplant centres to develop robust selection criteria to determine those patients who will benefit most from receiving a transplant. Previous studies by Wolfe *et al.* \[[@sfx117-B1]\] and Gill *et al.* \[[@sfx117-B4]\] have shown survival benefits of kidney transplantation in various groups of patients. In this study, we wanted to assess if it was possible to demonstrate this effect in a single transplant centre experience. Therefore, comparing the survival of KTR with the survival of patients awaiting transplantation and non-listed dialysis patients in Ireland was the main aim of this study.

Materials and methods
=====================

Study population and data source
--------------------------------

We carried out an analysis of the National Renal Transplant Registry and the Beaumont Hospital Renal Database (Clinical Vision 3.4a Version 1.1.34.1, Clinical Computing, Cincinnati, OH, USA) from 1 January 2004 to 31 December 2013, to determine the mortality of KTR, dialysis patients on the transplant waiting list and non-listed dialysis patients. This registry is maintained prospectively by dedicated full-time staff. A total of 1538 adult renal transplants were performed during this study period. The National Kidney Transplant Centre at Beaumont Hospital has performed all adult renal transplants in Ireland since 1987 (previous transplant surgery in Ireland was performed at the Charitable Infirmary, Jervis Street, since 1964). Elderly patients with an age of ≥70 years comprised \<0.5% of KTRs and hence they were excluded from this study. We also excluded patients who received a pre-emptive kidney transplant and recipients of a living-donor transplant.

Analytical methods
------------------

Analysis of survival was from the time of initial inclusion in the transplant waiting list to the time of death. We censored data when the patient received the first transplant from a living donor or on 31 December 2013. Some patients switched between the dialysis and the transplantation groups during follow-up and hence time-dependent, non-proportional hazards analysis was used to account for this switching. We calculated the number of days between inclusion in the transplant waiting list and the time at which the death rates equalized in the two groups; we calculated cumulative survival probabilities as well. Both calculations were adjusted for the time spent on the waiting list. The analyses were adjusted for age, sex, year of placement on the waiting list, time from first dialysis for ESKD to inclusion in the waiting list and the cause of ESKD. The latter was classified into subgroups of diabetes mellitus, glomerulonephritis or others. The loss of an allograft and the removal from the transplant waiting list did not exclude affected patients from the analyses. Analyses were conducted according to the intention to treat analysis. All data were analysed using STATA Version 10.0 (College Station, TX, USA). P \<  0.05 was considered to be statistically significant.

Results
=======

During the study period, 10 years, a total of 3597 patients were commenced on dialysis. Subsequently, 1157 patients were placed on the transplant waiting list, 990 received a deceased-donor kidney and 1450 were not eligible for transplantation. Mean age (standard deviation) was 46 (±15) years. Mean follow-up was 2.5 years. Baseline characteristics of the study population are shown in Table [1](#sfx117-T1){ref-type="table"}. Table 1.Characteristics of the study populationCharacteristicAll patients on dialysisPatients on the waiting listDeceased-donor transplant recipientsP-value*n* = 1450*n* = 1157*n* = 990Age number (%) ≤19 years58 (4)97 (8)62 (6)\<0.001 20--39 years317 (22)372 (32)334 (34) 40--59 years615 (42)517 (45)436 (44) 60--70 years460 (32)171 (15)158 (16)Sex Male923 (64)751 (65)624 (63)0.646 Female527 (36)406 (35)366 (37)Cause of ESKD Diabetes mellitus141 (10)66 (6)57 (6)\<0.001 Glomerulonephritis214 (15)230 (20)214 (22) Others1095 (75)861 (74)719 (72)

The group of patients on dialysis but not on the transplant waiting list had an annual death rate that was seven times higher than the group of patients on the waiting list. The annual death rate for patients on the waiting list was twice as high as that for KTR (Table [2](#sfx117-T2){ref-type="table"}). The unadjusted annual death rate per 100 patient-years at risk was 1.2 for KTRs, 2.4 for patients on the waiting list and 16.5 for all patients on dialysis (Table [2](#sfx117-T2){ref-type="table"}). Table 2.Annual death rates per 100 patient-yearsVariablePatients on dialysis not on pool (rate per 100 patient-years)Patients on the transplant waiting list (rate per 100 patient-years)Recipients of deceased-donor transplants (rate per 100 patient-years)All patients16.52.41.2Age (years) 0--1912.90.80.0 20--393.12.10.3 40--5914.22.30.9 60--7023.23.94.7Sex Male16.52.51.1 Female16.62.11.5Cause of ESKD Diabetes19.05.53.8 Other16.12.11.1

Compared with dialysis patients on the transplant waiting list, the relative risk of death was five times higher for patients on dialysis not on the transplant waiting list \[RR, 4.90; 95% confidence interval (CI), 3.70--6.52; P \< 0.001\].

[Figure 1](#sfx117-F1){ref-type="fig"} shows the adjusted relative risk of death among KTR, as compared with patients on the waiting list. Relative risk was adjusted for age, sex and diabetes as the cause of ESKD and other causes of ESKD. The relative risk of death was significantly lower in transplant recipients among each subgroup except for the age 60--70 years subgroup. However, the relative risk in the latter subgroup was not statistically significant.

![Relative risk of death for transplant recipients compared with on-pool dialysis patients. Subgroups were classified according to age, sex and diabetes as the cause of ESKD and other causes of ESKD. The relative risk was adjusted for age, sex and diabetes as the cause of ESKD and other causes of ESKD.](sfx117f1){#sfx117-F1}

A comparison was made between KTRs and patients on the waiting list who had not yet received a deceased-donor kidney transplant, but who had equal lengths of follow-up since placement on the waiting list; patients with unsuccessful transplantation were included in this comparison. During the first 4 weeks after transplantation, the adjusted relative risk of death among the KTRs was 1.7 times higher than the risk among patients on the transplant waiting list. This risk continued to increase during the first 12 weeks and peaked at 1.9 times as high by the end of Week 12. Although this risk of death started to fall thereafter, it remained elevated until 1 year post-transplantation. After this time, the risk was lower among the KTRs ([Figure 2](#sfx117-F2){ref-type="fig"}). The 5-year mortality risk was estimated to be 47% lower than that of patients on the waiting list (RR, 0.53; 95% CI, 0.37--0.77; P = 0.001).

![Adjusted relative risk of death for transplant recipients compared with on-pool dialysis patients during the first 5 years post-transplant. The reference group was the 1157 patients on dialysis who were on the transplant waiting list (RR, 1.0). Values were adjusted for age, sex cause of ESKD, year of placement on the waiting list and time from first treatment for ESKD to placement on the waiting list.](sfx117f2){#sfx117-F2}

Discussion
==========

Our analysis showed that transplantation improved survival in KTRs. In the subgroups analysis, according to age, sex and cause of ESKD, the mortality rate for all patients on dialysis was five times higher than that of patients who were on the transplant waiting list. These findings prove the fact that there is substantial selection of healthier patients for placement on the waiting list for transplantation.

The annual relative risk of death in our cohort was 1.2 per 100 patient-years for deceased-donor transplant recipients. This risk is lower compared with findings reported in previous studies \[[@sfx117-B1], [@sfx117-B3]\]. Wolfe *et al*. reported a relative risk of 3.8 in their cohort \[[@sfx117-B1]\]. Gill *et al.* stratified this relative risk of death according to waiting times for transplantation \[[@sfx117-B3]\]. They showed a risk of 4.0 per 100 patient-years for deceased-donor transplant recipients who waited for up to 36 months before transplantation. Waiting times beyond 36 months increased the risk to 5.4 \[[@sfx117-B3]\].

Another important finding demonstrated by our study was that the relative risk of death among KTR, who received their first transplant, relative to that among patients on the transplant waiting list varies significantly with time. Mortality was higher in the transplantation group immediately after transplantation. This finding was demonstrated in previous studies \[[@sfx117-B1], [@sfx117-B4]\]. The leading cause of death during the early post-transplantation period is cardiovascular disease \[[@sfx117-B9]\]. Previous studies have shown the importance of optimizing the management of cardiovascular risk factors in wait-listed patients by coordination between nephrologists and transplant teams \[[@sfx117-B10]\]. Unfortunately, so far no studies have shown a strategy or an intervention to reduce cardiovascular mortality during the early post-transplant period \[[@sfx117-B11]\]. Other important causes of high mortality in the early post-transplantation period are complications of surgery and effects of immunosuppression medications at high doses. Subsequently, the risk of death decreased and the survival benefit began to be observed (time to equal survival) 365 days after transplantation. In comparison with our findings, Wolfe *et al*. demonstrated a shorter time to equal survival, i.e. 244 days \[[@sfx117-B1]\]. We think the most likely explanation for this difference is that our waiting list, i.e. patients in Ireland, are healthier compared with their counterparts in USA, because of the stringent criteria used for inclusion into the kidney transplant pool in Ireland. This long-term improvement in survival was significant for all patients' subgroups, when compared with the survival rate among corresponding dialysis patients on the transplant waiting list. The excess early mortality after transplantation remains an important consideration that should be addressed adequately when counselling potential transplant recipients.

Both Wolfe *et al*. and Gill *et al*. showed that elderly transplant recipients\' survival benefits from transplantation when compared with dialysis patients on the transplant waiting list \[[@sfx117-B1], [@sfx117-B4]\]. We found that transplant recipients with ages 60--70 years had a higher risk of death by 1.2 times than those on the transplant waiting list. However, this finding was not statistically significant. Gill *et al*. showed that the time to equal survival was 521 days and 470 days for elderly recipients of a deceased-donor kidney transplant, with high cardiovascular risk and low cardiovascular risk, respectively \[[@sfx117-B4]\]. Schaeffner *et al*. demonstrated that only 7% of patients who are ≥65 years of age are transplanted after 3 years of initiating dialysis \[[@sfx117-B12]\]. Schold *et al*. showed that the 5-year probability of deceased-donor transplantation in patients aged ≥65 years is nearly equal to the probability of death on the waiting list \[[@sfx117-B13]\]. This reflects the importance of longer follow-up periods, where the survival benefit in the elderly becomes more apparent in subsequent years following transplantation. In contrast to this, the survival of elderly dialysis patients on the waiting list reduces significantly year after year. Therefore, a short follow-up period might be misleading when comparing the elderly patients' survival, and might show a better survival in the waiting-list cohort than in transplant recipients. Additionally, Gill *et al*. demonstrated that, in low cardiovascular risk patients, living-donor kidney transplantation was associated with an immediate survival advantage compared with dialysis \[[@sfx117-B4]\].

Our study has a number of strengths. Generally, in this study, we employed similar methods to those used by Wolfe *et al*. \[[@sfx117-B1]\]. An important strength is that we used an intention to treat analysis and hence mortality post-transplantation assessment was independent of allograft function. This type of analysis also allows comparison of KTRs with patients on the transplant waiting list who had equal lengths of time on the waiting list. This approach and methodology have previously been used in other studies \[[@sfx117-B1], [@sfx117-B14]\]. The estimation of time to equal risk and equal survival in this study was determined in KTRs compared with similar risk patients who remained on the waiting list, and differs from that in the study done by Merion *et al.* \[[@sfx117-B17]\]. In their study, the outcomes after Extended Criteria Donor transplantation were compared with continued waiting on the transplant waiting list and transplantation from a standard criteria deceased donor. As a result, the times to equal risk and equal survival among Extended Criteria Donor recipients are longer than those among KTRs in this study. We adjusted for the year of placement on the transplant waiting list and the interval between placement on the transplant waiting list and transplantation; this helped to minimize the potential effects of outcomes improvement over time.

This study has some limitations. Firstly, we did not study the use of transplants from living donors, although it has a better outcome than deceased-donor transplantation \[[@sfx117-B18], [@sfx117-B19]\]. Secondly, although our multivariate analyses were adjusted for differences in a variety of factors that impact transplant outcome, there are undoubtedly unaccounted differences between standard and Extended Criteria Donor recipients in this study that may confound our findings. Thirdly, despite including a reasonable number of transplant recipients in Ireland, the results may be difficult to apply to individual patients. Fourthly, in the last two decades, both short- and long-term survival have been improving for patients on dialysis and transplant recipients \[[@sfx117-B20]\], and this could affect our results. Finally, limitations of observational studies and secondary analyses of registry data cannot be overlooked when appraising this study.

In conclusion, this study, based on Irish data, shows that dialysis patients who were on the transplantation waiting list had a better survival when compared with dialysis patients who were not listed. First-time KTRs, who received a deceased-donor kidney transplant, had a higher risk of death initially when compared with dialysis patients who remained on the transplant waiting list, but their long-term survival was better. Time to equal survival was longer compared with other studies; this could be explained by better survival rates in our waiting list cohort. However, this excess early mortality after transplantation remains an important consideration that should be addressed adequately when counselling potential transplant recipients about transplantation.
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